João Ferreira, investigator from RISE/FMUP, participated in the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum, at Washington DC, USA. The CVCT forum is the largest global meeting dedicated to clinical trials in cardiovascular medicine, where he presented the results from the INITIATE-HFrEF trial (Simultaneous or sequential initiation of ARNI and SGLT2i in patients with HFrEF).
The Global CVCT Forum brings together key stakeholders from academia, industry, regulatory bodies, and clinical practice, providing a high-level platform for an in-depth discussion of major and recent clinical trials in cardiovascular disease. Participation in this forum underscores the international relevance of investigator-initiated research developed in Portugal.
During the congress, the rationale and design of the INITIATE-HFrEF study were highlighted, focusing on optimal strategies for initiating guideline-directed medical therapy in patients with heart failure with reduced ejection fraction (HFrEF). The trial investigates whether the simultaneous or sequential initiation of ARNI and SGLT2 inhibitors results in differences in clinical outcomes and treatment optimisation. Importantly, the INITIATE-HFrEF trial has now been completed, and the first results are expected to be released soon, contributing new evidence to inform clinical decision-making in heart failure management.
© Photo: Global CardioVascular Clinical Trialists Forum
